Seres Therapeutics, Inc.
Developing live biotherapeutics from the microbiome to treat infections and immune diseases.
MCRB | NDAQ
Overview
Corporate Details
- ISIN(s):
- US81750R2013
- LEI:
- Country:
- United States of America
- Address:
- 200 SIDNEY STREET, 2139 CAMBRIDGE
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Seres Therapeutics, Inc. is a commercial-stage biotechnology company pioneering the development of live biotherapeutics. The company focuses on modulating the gastrointestinal microbiome to treat serious diseases. Its platform creates rationally designed consortia of live bacteria intended to transform the lives of medically vulnerable patients. Seres Therapeutics' programs target the prevention of bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as the treatment of gastrointestinal-related immune diseases such as inflammatory bowel disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Seres Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Seres Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Seres Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
